| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Advancing drug development in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Allogeneic bone marrow transplantation for aplastic anemia |
|
International Journal of Hematology |
Aplastic Anemia |
| Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades |
|
Blood Advances |
Aplastic Anemia |
| Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
